CliffBio
biologic

ALTUVIIIO

antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl

Loss of exclusivityFebruary 2035projected — 12-year biologic exclusivity estimate
CompanyBioverativ →View the full company profile on CliffBio

Drug detail

Brand nameALTUVIIIO
Active ingredientantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl
Strength4000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2023
Marketing statusRx

More from Bioverativ

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

ALTUVIIIO patent cliff — loss of exclusivity February 2035 | CliffBio